Biogen Marks Time As Biosimilars Business Keeps Ticking Over

Firm Also Discusses Threats To Tecfidera And Tysabri MS Franchises

 
• By Dave Wallace
  
Biogen’s biosimilars business enjoyed growth in 2024 (Shutterstock)

More from Earnings

More from Products